Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011169 | 0.87 | LMNA (0.57) | PLA2G2ALMNAKDM4EMAPK1NPSR1 | |
| SCHEMBL2014731 | 0.84 | PLA2G2A (0.49) | PLA2G2ATSHRHTTLMNAKDM4E | |
| SCHEMBL3159333 | 0.79 | MEN1 (0.54) | TSHRHTTLMNAKDM4EMAPK1 | |
| SCHEMBL2014108 | 0.76 | PLA2G2A (0.45) | PLA2G2ATSHRHTTLMNAKDM4E | |
| SCHEMBL2015666 | 0.76 | PLA2G2A (0.50) | PLA2G2ATSHRHTTLMNAKDM4E | |
| SCHEMBL27888615 | 0.76 | ALDH1A1 (0.58) | LMNAKDM4EMAPK1NPSR1HPGD | |
| SCHEMBL13652181 | 0.76 | KDM4E (0.49) | LMNAKDM4EMAPK1NPSR1HPGD | |
| SCHEMBL2014648 | 0.75 | ERN1 (0.56) | LMNAKDM4EMAPK1NPSR1HPGD | |
| SCHEMBL2313075 | 0.74 | LMNA (0.56) | LMNAKDM4EMAPK1NPSR1HPGD | |
| SCHEMBL6270490 | 0.74 | KDM4E (0.50) | TSHRHTTLMNAKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721034-B1 | N-HETEROTRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140235855-A1 | Tricyclic Antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2721034-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012171860-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-12-20 | — | — | WO | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | PLA2G2A 3163/4885TSHR 543/4885HTT 4381/4885 |
| US-20140235855-A1 | Tricyclic Antibiotics | CBR1, CYP2S1, C1S | PLA2G2A 3167/4885TSHR 1809/4885HTT 4710/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | PLA2G2A 4774/4885TSHR 2798/4885HTT 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.